The objective of this clinical trial is to evaluate the safety and effectiveness of the Carl Zeiss Meditec VisuMax™ Femtosecond Laser lenticule removal procedure for the reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE (Manifest Refractive Spherical Equivalent) ≤ -8.25 D.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Effectiveness- Predictability of Participant Refractive Outcomes
Timeframe: 12 months
Effectiveness- Number of Participants With an Improvement in UCVA Following Treatment
Timeframe: 12 month
Stability Criteria- Number of Participants With a Change Between Visits Within 1.00 Diopter (D)
Timeframe: 6 months
Safety- Number of Participants With a Preservation of Best-Spectacle Corrected Visual Acuity (BSCVA)
Timeframe: 12 months
Safety- Number of Participants With Induced Manifest Refractive Astigmatism
Timeframe: 12 months
Safety- Number of Participants With Adverse Events
Timeframe: 12 months
Safety- Contrast Sensitivity of Participants
Timeframe: 12 months
Stability Criteria- Number of Participants With a Change Between Visits Within 0.50 Diopter (D)
Timeframe: 6 months